iTAC Software AG: Closed Loop: Simulating, planning and managing the digital factory
24.5.2023 14:48:14 CEST | news aktuell GmbH | Press release
The factory of the future is digital and relies on integrated, rather than isolated, solutions. The software companies DUALIS GmbH IT Solution (www.dualis-it.de) and iTAC Software AG (www.itacsoftware.com) developed a holistic digitalization approach for greater efficiency, flexibility and quality in manufacturing. In the closed loop model, simulation, APS and MES/MOM are closely interlinked and interact with each other. This means, for example, that manufacturing processes can be optimized end-to-end. At the same time, costs and risks can be minimized.
One element of the holistic digitization approach is the digital twin. Using the 3D simulation platform Visual Components, which is supplied by DUALIS, users can create digital twins of their entire production and simulate material and process flows. This allows systems, components, and processes to be tested before they are used in practice, "what-if" scenarios to be run through and errors to be minimized.
Based on these simulation results, a model for realistic production planning can be generated with the GANTTPLAN advanced planning and scheduling system (APS) from DUALIS. The APS carries out planning across departments and takes the entire value chain into account.
At the same time, the data from the digital twin is transferred directly to iTAC Software AG's iTAC.MOM.Suite manufacturing operations management system. This forms the necessary interface between production and IT systems and enables real-time monitoring of production processes. If the MOM knows the current state, the APS can precisely calculate the future.
This marks the closed loop approach: the real data from the MOM and APS system is sent back to the simulation for continuous optimization of the process flows. Changes in key figures and throughputs can then be viewed and evaluated.
iTAC Software AG
Alina Leber
+(49)26021065211
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
FRITZ: YouGov survey in 14 countries: Trust in router manufacturers from different regions European consumers mistrust Chinese routers29.6.2026 10:00:00 CEST | Press release
More than half of consumers in Norway mistrust routers from Chinese manufacturers (59%) Many mistrust devices made in the USA European routers enjoy a high level of trust across Europe (60%) For half of Europeans (55%), the ‘Made in Europe’ label important to when making a purchase
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom